These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 39072530)

  • 1. Treatment controversies in spondyloarthritis and psoriatic arthritis: focus on biologics and targeted therapies.
    Kharouf F; Gladman DD
    Expert Rev Clin Immunol; 2024 Nov; 20(11):1381-1400. PubMed ID: 39072530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of infections in psoriatic arthritis or axial spondyloarthritis patients treated with targeted therapies: A meta-analysis of randomized controlled trials.
    Séauve M; Auréal M; Laplane S; Lega JC; Cabrera N; Coury F
    Joint Bone Spine; 2024 May; 91(3):105673. PubMed ID: 38042364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Updated guidelines for the management of axial disease in psoriatic arthritis.
    Nash P; Lubrano E; Cauli A; Taylor WJ; Olivieri I; Gladman DD
    J Rheumatol; 2014 Nov; 41(11):2286-9. PubMed ID: 25362712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Depression/anxiety symptoms in axial spondyloarthritis and psoriatic arthritis patients in Serbia: a pilot study.
    Milutinovic S; Veljkovic K; Zlatanovic M; Radunovic G; Damjanov N
    Rheumatol Int; 2019 Sep; 39(9):1595-1605. PubMed ID: 31309294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disease-modifying Antirheumatic Drugs (DMARD) and Combination Therapy of Conventional DMARD in Patients with Spondyloarthritis and Psoriatic Arthritis with Axial Involvement.
    Simone D; Nowik M; Gremese E; Ferraccioli GF
    J Rheumatol Suppl; 2015 Nov; 93():65-9. PubMed ID: 26523061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis - A nationwide cohort study from the DANBIO and DERMBIO registries.
    Egeberg A; Rosenø NAL; Aagaard D; Lørup EH; Nielsen ML; Nymand L; Kristensen LE; Thyssen JP; Thomsen SF; Cordtz RL; Loft N; Skov L; Bryld LE; Rasmussen MK; Højgaard P; Kristensen S; Dreyer L
    Semin Arthritis Rheum; 2022 Apr; 53():151979. PubMed ID: 35183936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treating axial and peripheral spondyloarthritis, including psoriatic arthritis, to target: results of a systematic literature search to support an international treat-to-target recommendation in spondyloarthritis.
    Schoels MM; Braun J; Dougados M; Emery P; Fitzgerald O; Kavanaugh A; Kvien TK; Landewé R; Luger T; Mease P; Olivieri I; Reveille J; Ritchlin C; Rudwaleit M; Sieper J; Smolen JS; Wit Md; van der Heijde D
    Ann Rheum Dis; 2014 Jan; 73(1):238-42. PubMed ID: 23740234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis.
    Cantini F; Niccoli L; Nannini C; Cassarà E; Kaloudi O; Giulio Favalli E; Becciolini A; Biggioggero M; Benucci M; Li Gobbi F; Grossi V; Infantino M; Meacci F; Manfredi M; Guiducci S; Bellando-Randone S; Matucci-Cerinic M; Foti R; Di Gangi M; Mosca M; Tani C; Palmieri F; Goletti D;
    Semin Arthritis Rheum; 2016 Apr; 45(5):519-32. PubMed ID: 26607440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An overview of biologic disease-modifying antirheumatic drugs in axial spondyloarthritis and psoriatic arthritis.
    So A; Inman RD
    Best Pract Res Clin Rheumatol; 2018 Jun; 32(3):453-471. PubMed ID: 31171315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The 2023 pipeline of disease-modifying antirheumatic drugs (DMARDs) in clinical development for spondyloarthritis (including psoriatic arthritis): a systematic review of trials.
    Denis A; Sztejkowski C; Arnaud L; Becker G; Felten R
    RMD Open; 2023 Jul; 9(3):. PubMed ID: 37507210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First-time prescriptions of biological disease-modifying antirheumatic drugs in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis 2002-2011: data from the NOR-DMARD register.
    Lie E; Fagerli KM; Mikkelsen K; Rødevand E; Lexberg A; Kalstad S; Uhlig T; Kvien TK
    Ann Rheum Dis; 2014 Oct; 73(10):1905-6. PubMed ID: 24989896
    [No Abstract]   [Full Text] [Related]  

  • 12. Management of Axial Spondyloarthritis - Insights into Upadacitinib.
    Braun J; Kiltz U; Baraliakos X
    Drug Des Devel Ther; 2022; 16():3609-3620. PubMed ID: 36268520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is precision medicine possible in rheumatic diseases? Lessons from selective use of targeted therapies in patients with psoriatic arthritis.
    Miyagawa I; Tanaka Y
    Expert Rev Clin Immunol; 2020 Feb; 16(2):199-206. PubMed ID: 31905298
    [No Abstract]   [Full Text] [Related]  

  • 14. The approach to precision medicine for the treatment of psoriatic arthritis.
    Miyagawa I; Tanaka Y
    Immunol Med; 2020 Sep; 43(3):98-102. PubMed ID: 32306849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of body mass index on treatment response of biologic/targeted-synthetic DMARDs in patients with rheumatoid arthritis, psoriatic arthritis or axial spondyloarthritis. A systematic review.
    Gialouri CG; Pappa M; Evangelatos G; Nikiphorou E; Fragoulis GE
    Autoimmun Rev; 2023 Jul; 22(7):103357. PubMed ID: 37150489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peripheral spondyloarthritis: a neglected entity-state of the art.
    Carron P; De Craemer AS; Van den Bosch F
    RMD Open; 2020 May; 6(1):. PubMed ID: 32385142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High disease relapse after bDMARD spacing in psoriatic arthritis compared to rheumatoid arthritis and axial spondyloarthritis patients: real-life data from BIOPURE registry.
    Fornaro M; Righetti G; Abbruzzese A; Lopalco G; Cacciapaglia F; Anelli MG; Venerito V; Iannone F
    Clin Rheumatol; 2021 Sep; 40(9):3659-3665. PubMed ID: 33864158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disease characteristics, pathogenesis, and treatment controversies of axial psoriatic arthritis.
    Yousif P; Nahra V; Khan MA; Magrey M
    Joint Bone Spine; 2024 Jan; 91(1):105625. PubMed ID: 37495073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging drugs for the treatment of axial and peripheral spondyloarthritis.
    Braun J; Kiltz U; Heldmann F; Baraliakos X
    Expert Opin Emerg Drugs; 2015 Mar; 20(1):1-14. PubMed ID: 25575936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. JAK inhibitors, psoriatic arthritis, and axial spondyloarthritis: a critical review of clinical trials.
    Keeling S; Maksymowych WP
    Expert Rev Clin Immunol; 2021 Jul; 17(7):701-715. PubMed ID: 33944642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.